Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer

Medical Oncology

Volumn 31, Issue 7, 2014, Pages

  Zhu, Kunli ^a   Yan, Hongjiang ^a   Wang, Renben ^a   Zhu, Hui ^a   Meng, Xiangjiao ^a   Xu, Xiaoqing ^a   Dou, Xue ^a   Chen, Dong ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

BRAF; KRAS; Metastatic colorectal cancer; Mutation; PIK3CA

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; MALE; MUTATION RATE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PYROSEQUENCING; SIGNAL TRANSDUCTION; AGED; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY;

AGED; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84901573827     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0016-6     Document Type: Article

References (28)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365:153-65. (Pubitemid 40091806)
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
3. Cutsem EV, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64. (Pubitemid 46797944)
4. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249-79. (Pubitemid 44301348)
5. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268-72. (Pubitemid 44497237)
6. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of K-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomark Prev. 2000;9:1193-7.
7. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis. 2003;24:703-10. (Pubitemid 36592405)
8. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54. (Pubitemid 34716871)
9. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-6.
10. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561-73. (Pubitemid 40799249)
11. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidy-linositol-3-OH kinase as a direct target of Ras. Nature. 1994;370:527-32. (Pubitemid 24264918)
12. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110a is required for ras-driven tumorigenesis in mice. Cell. 2007;129:957-68. (Pubitemid 46802703)
13. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. (Pubitemid 38541907)
14. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41:1649-54. (Pubitemid 40981849)
15. Barault L, Veyrie N, Jooste V, et al. Mutations in the RASMAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008;122:2255-9. (Pubitemid 351542328)
16. Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer. 2007;121:1771-8. (Pubitemid 47417296)
17. Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009;27:1477-84.
18. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10:534-41. (Pubitemid 351770297)
19. Stephan B, Karl LS, Rainer E, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16(3):790-9.
20. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30(24):2956-62.
21. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7(3):413-21. (Pubitemid 41149657)
22. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347-51. (Pubitemid 46328493)
23. Simi L, Pratesi N, Vignoli M, et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol. 2008;130:247-53.
24. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17(5):1122-30.
25. Richman SD, Seymour M, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27(35):5931-7.
26. Ree AH, Kristensen AT, Saelen MG, et al. Tumor phosphatidy-linositol-3- kinase signaling and development of metastatic disease in locally advanced rectal cancer. PLoS One. 2012;7(11):50806.
27. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC23, EORTC 40993, SAKK 60200 trial. J Clin Oncol. 2010;28(3):466-74.
28. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18(8):2257-68.